HR+/HER2+ and HR‐/HER2‐ BC detection decreased in 2020 (−4.1% [−6.3%, −1.8%] and −4.1% [−6.5%, −1.7%], respectively) and exceeded projections in 2021 (5.8% [3.2%, 8.3%] and 6.6% [4.0%, 9.2%], respectively). Here, ERBB2 is linked to breast cancer.